Palonosetron

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

38 Suppliers, 22 USDMF, 3 JDMF, 9 EU WC, 4 KDMF, 14 NDC API, 23 Listed Suppliers

DEVELOPMENTS

8 Drug(s) in Development

8 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Imports

INTERMEDIATES

11 Suppliers

11 Suppliers

DOSSIERs // Finished Dosage Forms

81 Dossiers, 34 FDA Orange Book, 13 Europe, 3 Canada, 4 Australia, 5 South Africa, 22 Listed Dossiers

DRUG PRODUCT COMPOSITION

CAPSULE;ORAL - 300MG;EQ 0.5MG BASE, SOLUTION;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML), POWDER;INTRAVENOUS - EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL, SOLUTION;INTRAVENOUS - EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML), INJECTABLE;INTRAVENOUS - EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers, 22 Roquette, 15 SPI Pharma, 10 Gangwal Healthcare, 9 Microlex e.U, 9 Sigachi Industries, 6 Kerry, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 6 Actylis, 5 Gangwal Chemicals, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 4 Prachin Chemical, 4 ACG Worldwide, 3 DFE Pharma, 3 Vasa Pharmachem, 3 Lonza Capsugel, 2 Pharmatrans-Sanaq, 2 Boai NKY Pharmaceuticals Ltd, 2 DKSH, 2 Shijiazhuang Huaxu Pharmaceutical, 2 Jai Radhe Sales, 2 Nanjing Well Pharmaceutical, 2 Rochem International Inc, 2 Ingredion Pharma Solutions, 1 Pfanstiehl, 1 NEWEDGE Overseas, 1 Chynops Pharma, 1 Minakem, 1 Ideal Cures Pvt Ltd, 1 Alcedo Pharmachem, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Ulanqab Kema New Material, 1 Qualicaps, 1 Zhejiang Huakang Pharmaceutical, 1 BASF

EXCIPIENTS BY APPLICATIONS

46 Fillers, Diluents & Binders, 20 Direct Compression, 18 Lubricants & Glidants, 17 Disintegrants & Superdisintegrants, 14 Chewable & Orodispersible Aids, 14 Taste Masking, 12 Thickeners and Stabilizers, 11 Co-Processed Excipients, 10 Parenteral, 10 Film Formers & Plasticizers, 10 Granulation, 9 Coating Systems & Additives, 8 Empty Capsules, 7 Controlled & Modified Release, 3 API Stability Enhancers, 2 Rheology Modifiers, 2 Emulsifying Agents, 1 Soft Gelatin, 1 Solubilizers

GLOBAL SALES INFORMATION

14 US Medicaid Prescriptions, 11 Finished Drug Prices

MARKET PLACE

6 APIs, 6 DOSSIERS // FDF

PATENTS

75 US Patents, 3 Health Canada Patents

ANALYTICAL SOLUTION(s)

7 USP Standards, 7 Other Ref. Standards

DIGITAL CONTENT

2 Data Compilation & Company Tracker #PharmaFlow, 59 News

Information, Expiry & Status of FDA Orange Book Patents covering Palonosetron

Palonosetron

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

38 Suppliers

22 USDMF

3 JDMF

9 EU WC

4 KDMF

14 NDC API

23 Listed Suppliers

DEVELOPMENTS

8 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Imports

INTERMEDIATES

11 Suppliers

DOSSIERs // Finished Dosage Forms

81 Dossiers

34 FDA Orange Book

13 Europe

3 Canada

4 Australia

5 South Africa

22 Listed Dossiers

DRUG PRODUCT COMPOSITION

CAPSULE;ORAL - 300MG;EQ 0.5MG BASE

SOLUTION;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

POWDER;INTRAVENOUS - EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL

SOLUTION;INTRAVENOUS - EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)

INJECTABLE;INTRAVENOUS - EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers

22 Roquette

15 SPI Pharma

10 Gangwal Healthcare

9 Microlex e.U

9 Sigachi Industries

6 Kerry

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

6 Actylis

5 Gangwal Chemicals

5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

4 Prachin Chemical

4 ACG Worldwide

3 DFE Pharma

3 Vasa Pharmachem

3 Lonza Capsugel

2 Pharmatrans-Sanaq

2 Boai NKY Pharmaceuticals Ltd

2 DKSH

2 Shijiazhuang Huaxu Pharmaceutical

2 Jai Radhe Sales

2 Nanjing Well Pharmaceutical

2 Rochem International Inc

2 Ingredion Pharma Solutions

1 Pfanstiehl

1 NEWEDGE Overseas

1 Chynops Pharma

1 Minakem

1 Ideal Cures Pvt Ltd

1 Alcedo Pharmachem

1 Shanghai Welltone Material Technology Co., Ltd

1 Ulanqab Kema New Material

1 Qualicaps

1 Zhejiang Huakang Pharmaceutical

1 BASF

EXCIPIENTS BY APPLICATIONS

46 Fillers, Diluents & Binders

20 Direct Compression

18 Lubricants & Glidants

17 Disintegrants & Superdisintegrants

14 Chewable & Orodispersible Aids

14 Taste Masking

INJECTABLE;INTRAVENOUS - EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INTRAVENOUS - EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 0.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons